Gland Pharma Limited has informed the Exchange about Investor Presentation
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported strong Q4 FY26 results with revenue from operations at ₹17,428 million (up 22% YoY) and full year FY26 revenue at ₹64,307 million (up 14%). Adjusted EBITDA for Q4 FY26 stood at ₹5,244 million (up 51% YoY) with margins expanding to 30% from 24% in the same period last year. Adjusted PAT for Q4 FY26 was ₹3,667 million, nearly doubling from ₹1,865 million (up 97% YoY), with PAT margins improving to 21% from 13%. The company launched 31 products in the US in FY26, including Dalbavancin and Brimonidine in Q4. The cumulative ANDA count reached 388 filings with 337 approvals and 51 pending. The company signed a new CDMO contract for a complex Nano Drug Delivery System in oncology. The board recommended a final dividend of ₹20 per share. Cash position remains strong with net cash of ₹31,157 million.
The strong margin expansion and near-doubling of PAT demonstrates operational efficiency gains. The robust pipeline of complex injectables, RTU bags, and GLP-1 capacity positions the company well for sustained growth. The dividend and healthy cash reserves indicate financial strength.